Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 32

Results For "EDS"

1316 News Found

Wipro to implement Independent Health’s Medicare prescription payment plan platform
Digitisation | May 04, 2024

Wipro to implement Independent Health’s Medicare prescription payment plan platform

Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions


Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake
News | May 03, 2024

Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake

The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market


AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024
Diagnostic Center | May 02, 2024

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD


Novartis and Medicines for Malaria Venture announce positive efficacy and safety data
Diagnostic Center | May 01, 2024

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data

The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg


Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development
Digitisation | April 30, 2024

Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development

New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)


FDA approves Biktarvy label update with data for pregnant adults with HIV
Drug Approval | April 27, 2024

FDA approves Biktarvy label update with data for pregnant adults with HIV

Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV


AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
News | April 23, 2024

AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis

Open a printable version of this pageEmail the URL of this page to a friend


Voydeya approved in the EU as add-on treatment to ravulizumab
News | April 23, 2024

Voydeya approved in the EU as add-on treatment to ravulizumab

ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue


Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA
Drug Approval | April 22, 2024

Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA

NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A